Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy - HUDSON

Study identifier:D6185C00001

ClinicalTrials.gov identifier:NCT03334617

EudraCT identifier:2017-002208-28

CTIS identifier:N/A

Recruitment Complete

Official Title

An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON).

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Durvalumab, AZD9150, AZD6738, Vistusertib, Olaparib, Oleclumab, trastuzumab deruxtecan, cediranib, AZD6738 (ceralasertib), AZD6738 (ceralasertib) (240 mg or 160 mg), AZD6738 (ceralasertib) 7 days monotherapy

Sex

All

Actual Enrollment

531

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 18 Dec 2017
Estimated Primary Completion Date: 04 Sept 2024
Estimated Study Completion Date: 04 Sept 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria